pdufa
.bio
Calendar
Decisions
Research
Home
›
Decisions
› AZN 2026-05-28
AZN
FDA decision
— May 28, 2026
✓ APPROVED
AstraZeneca PLC — Imfinzi (durvalumab) · Non-Muscle Invasive Bladder Cancer (NMIBC).
Run-up into the decision (T-120 → T+5)
PDUFA 5/28/26
$209.48
$179.64
12/11/25
Daily close, T-120 (12/11/25) through T+5. Run-up high $209.48 on 2/19/26, low $179.64 on 12/17/25 (T-120 to T-1). FDA decision 5/28/26. Historical price action, not a forecast.
Key facts
FDA decision date
2026-05-28
Outcome
Approved
Drug / candidate
Imfinzi (durvalumab)
Company
AstraZeneca PLC
120-day run-up (T-120→T-1)
+2.2%
Not affiliated with or endorsed by the FDA.
Informational and educational only — not investment advice. Verify against primary FDA / SEC / company filings. © 2026 pdufa.bio